Sorafenat

Sorafenib is pharmacologically categorized as protein kinase inhibitor, which is FDA approved compound used for the treatment of primary renal cell cancer in advanced stage, metastatic liver carcinoma (sorafenib liver cancer) and also involved in radioactive iodine resistant advanced thyroid cancer. Sorafenib is considered as synthetic compound aiming signal responding for growth and angiogenesis. Sorafenib works by blocking the enzyme RAF kinase, which is a demanding component of the RAF/MEK/ERK signaling pathway that dominates cell separation and multiplication. On the other hand, Sorafenib also prohibits the VEGFR-2/PDGFR-beta signaling force, through blockade of tumor angiogenesis.

Sorafenib

Sorafenat

200mg

Natco




Sorafenat (Sorafenib) prescribing information

Sorafenib is available in the form of tablet, which is used in various conditions like;
Metastatic renal cell cancer
Metastatic Hepatocellular cancer
(Sorafenib hepatocellular carcinoma)
Thyroid cancer

Sorafenat (Sorafenib) mechanism of action

The activity of Sorafenat containing Sorafenib is developing in-vitro. Sorafenat expels its activity by prohibiting assorted intracellular & cell surface kinase which is important for tumor cell signaling exudation, angiogenesis and apoptosis.

Due to prohibition of these multikinases is a source of cancer growth termination. Reduction of cancer cell angiogenesis happens in HCC, RCC and elevation of cancer cell apoptosis occurs in HCC, RCC & TC



ADME PROPERTIES

The oral bioavailability of Sorafenat is occurs as 38 to 49%. The peak plasma concentration time of Sorafenat is 3 hours.

Sorafenib is highly bound to the human plasma protein at the range of 99.5%

Sorafenat is undergoes oxidative metabolism, intermediated by CYP3A4, in addition of Glucuronidation mediated by UGT1A9.

The excretion of Sorafenat occurs via urine, feces and biliary excretion also undergone. Overall 96% of dose should be replaced within 14 days, in which 77% excreted in feces; 19% in urine. The unchanged form of Sorafenib is around 51% should be recovered in feces and not in urine, biliary excretion also occurred. The half-life period of Sorafenat is relatively 25 to 48 hours.




Blueberrypharma.com

Sorafenat 200mg
Brand Sorafenat
Ingredients Sorafenib
Strength 200mg
Manufactured Natco
Rating


Dosage regimens of Sorafenat tablets

In HCC, RCC or TC condition: The usual prescribed dosage of Sorafenat is 400mg tablet (200mg×2 tablets) should be taken as two times a day.

Dosage alteration in severe conditions

Sorafenat tablets used therapy should be postponed for short period of time in major surgical procedures. Sorafenat tablets should be postponed or permanently discontinued for following conditions like; Hemorrhage, Cardiac ischemia, Severe hypertension, Gastrointestinal perforation, QTc prolongation, Liver injury

Dose variation in HCC & RCC

The dosage should be varied in HCC & RCC, if dose reduction is required. The dosage should be decreased to 400mg as a single dose. If further reduction is required, provide 400mg as a single dose for alternative day.

Dose variation in dermatological toxicities with HCC

Grade 1 toxicity: Extend the Sorafenat therapy and provide with topical therapy for symptomatic relief.
Grade 2 toxicity: Extend the Sorafenat therapy and provide with topical therapy for symptomatic relief. If it occurs continuously, discontinue the Sorafenat therapy.
Grade 3 toxicity: Discontinue the Sorafenat therapy, if it is needed the dose should be reduced by two times a day into single dose.

Dose alteration in thyroid carcinoma

First dose reduction: 600mg of Sorafenat should be recommend
Second dose reduction: 400mg of Sorafenat should be prescribed for two times a day
Third dose reduction: 200mg of Sorafenat should be prescribed as a single dose.

In concurrent use of CYP3A4 inducers

Sorafenat tablets should be co administered with CYP3A4 inducers like anti-convulsants; st.Johns wort etc causes decreasing the systemic exposure of Sorafenib. The efficiency of Sorafenib has not been established in pediatric patients. The Dosage should not be adjusted in elderly patients. In renal and hepatic impairment patients, no dosage adjustment should be recommended. Sorafenat tablets should be taken without food. Sorafenat tablets should be taken at least 1 hour earlier or 2 hours after a meal

Sorafenat tablet causes some adverse effects

Hypertension Myocardial infarction or ischemia Gastrointestinal perforation Drug caused hepatitis Hemorrhage

Most common side effects (Sorafenib)

Diarrhea, Alopecia, Infection, Hand foot skin reaction, Musculoskeletal disorders, Loss of weight, Increasing amylase & lipase

Post marketing adverse effects

Stevens Johnson syndrome, Angioedema, Rhabdomyolysis, Osteonecrosis, Interstitial lung disease, Folliculitis, Leucopenia, Neutropenia, Anemia, Thrombocytopenia, Hypothyroidism, Hypocalcaemia, Hypokalemia, Hyponatremia, Depression, Peripheral sensory neuropathy, Tinnitus, Congestive heart failure, Rhinorrhoea, Dysphonia, Gastro esophageal reflux

Safety measures
Some adverse reactions occur during the treatment with Sorafenat tablets;

Exposure of GI perforation
Stop the therapy of Sorafenat tablets.

Warfarin
Combination of Sorafenat with warfarin causes elevation of INR level. To avoid this problem monitor the patients bleeding (prothrombin time) frequently.

Wound healing complications
Sorafenat tablets should be postponed during surgical procedures, to prevent wound complications.

Elevation of mortality during combination of Sorafenatwith carboplatin/paclitaxel and gemcitabine/cisplatin in squamous lung cancer
This combination is contraindicated for the patients with squamous cell lung cancer.

Exposure of QT extension
Sorafenat causes prolongation of QT intervals; avoid this therapy in patients who have cardiac problems.

Therapy induced hepatitis
During the therapy with Sorafenat , causes elevation of transaminase leads to liver injury and causes liver failure.

Embryo fetal harm
Sorafenat tablet causes fetal harm

Thyroid stimulating hormone impairment in thyroid carcinoma
TSH level should be monitored frequently and adjust thyroid replacement.

Exposure of cardiac ischemia or infarction
To avoid this condition, postpone or discontinue the therapy

Exposure of hemorrhage
Permanent discontinuation of Sorafenat therapy

Exposure of hypertension
Monitor the blood pressure frequently and provide anti-hypertensive agents for this condition.

Other drugs

Sorafenat tablets while combining with Midazolam, dextromethorphan, or Omeprazole causes no elevation of systemic exposure of these drugs.

Antibiotics

While combining Sorafenat with antibiotic like neomycin causes depletion AUC of Sorafenib. The solubility of Sorafenat is depends upon pH, if pH increases causes decreasing the solubility.

Anti-cancer drugs

Combination of Sorafenat with other anti-neoplastic agents likes; Paclitaxel or carboplatin: Causes elevation of exposure of Sorafenib Capecitabine: Increase Capecitabine exposure Doxorubicin/Irinotecan: Elevation of AUC of doxorubicin and Irinotecan With neomycin: Intercede with enterohepatic recycling of Sorafenib, causes depletion of Sorafenib exposure.

CYP3A4 inducers

Sorafenat tablets combined with strong CYP3A4 inducers like rifampin causes decrease in AUC of Sorafenib. Avoid concurrent use of Sorafenat with strong CYP3A4 inducers like anti-convulsants, anti-mycobacterials& herbal product like st.Johns wort. This results as to cause loss of exposure to Sorafenib and leads to reduce the therapeutic effect of Sorafenat tablets.

CYP3A4 inhibitors

Sorafenat tablets are combined with strong CYP3A4 inhibitors like ketaconazole causes no variation in AUC of Sorafenib.



In patients with squamous cell lung cancer, are contraindicated in combination of Sorafenat with carboplatin & paclitaxel. Some anaphylactic reactions occur, if patients are contraindicated to the component of Sorafenat tablets.

The pregnancy category of Sorafenat tablet: D Sorafenat tablets should not be recommended in pregnancy conditions Breast feeding should not be recommended

Sorafenat tablet stored at 25°C (77°F). Protect the container from moisture, heat and light

Sorafenat tablet is a chemo drug, used only by the patients having a valid prescription If patients fail to take the dose of Sorafenat , must consult with medical practitioner and follow the instruction. On the other hand, the missed dose should be skipped and follow the regular dosing schedule.

Blueberrypharma.com-img2



Quick Contact




Prescription upload






PRESCRIPTION


Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.